Stock Research: Australian Clinical Labs

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Australian Clinical Labs

ASX:ACL AU0000148496
20
  • Value
    82
  • Growth
    16
  • Safety
    Safety
    12
  • Combined
    20
  • Sentiment
    57
  • 360° View
    360° View
    20
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 20 (better than 20% compared with alternatives), overall professional sentiment and financial characteristics for the stock Australian Clinical Labs are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Australian Clinical Labs. The consolidated Value Rank has an attractive rank of 82, which means that the share price of Australian Clinical Labs is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 82% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 57, which means that professional investors are more optimistic about the stock than for 57% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 16, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 12, meaning the company has a riskier financing structure than 88 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
ASX 300
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
82 n/a n/a n/a
Growth
16 n/a n/a n/a
Safety
Safety
12 n/a n/a n/a
Sentiment
57 n/a n/a n/a
360° View
360° View
20 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
30 n/a n/a n/a
Opinions Change
20 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
84 n/a n/a n/a
Sentiment
57 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
82 n/a n/a n/a
Growth
16 n/a n/a n/a
Safety Safety
12 n/a n/a n/a
Combined
20 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
82 n/a n/a n/a
Price vs. Earnings (P/E)
73 n/a n/a n/a
Price vs. Book (P/B)
27 n/a n/a n/a
Dividend Yield
100 n/a n/a n/a
Value
82 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
8 n/a n/a n/a
Profit Growth
24 n/a n/a n/a
Capital Growth
65 n/a n/a n/a
Stock Returns
18 n/a n/a n/a
Growth
16 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
1 n/a n/a n/a
Refinancing
34 n/a n/a n/a
Liquidity
42 n/a n/a n/a
Safety Safety
12 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to Australian Clinical Labs and broaden your portfolio horizons.

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Alfresa Holdings

TYO:2784
Country: Japan
Industry: Health Care Distributors
Size: X-Large
Full Stock Analysis

Kyowa Hakko Kirin

TYO:4151
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Astellas Pharma

TYO:4503
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

With good value and positive sentiment, but low growth and risky financing, this combination is generally dangerous as debt requires growth to sustain it. Only investors with a strong belief in future growth potential and a high-risk tolerance should consider this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: